SOD1 Mutations in Amyotrophic Lateral Sclerosis

SOD1 Mutations in Amyotrophic Lateral Sclerosis

Overview

Mutations in the SOD1 (Superoxide Dismutase 1) gene are the second most common cause of familial amyotrophic lateral sclerosis (ALS), accounting for approximately 15-20% of inherited ALS cases and representing one of the most extensively studied genetic contributors to motor neuron disease[@banci2007][@strong2010]. Over 180 pathogenic mutations have been identified throughout the SOD1 gene, making it the ALS gene with the largest number of known disease-causing variants. The discovery in 1993 that SOD1 mutations cause ALS through a toxic gain-of-function mechanism revolutionized our understanding of ALS pathogenesis and provided the first clear evidence that protein misfolding and aggregation are central to motor neuron degeneration[@prudencio2009].

Introduction

Amyotrophic lateral sclerosis is a devastating neurodegenerative disorder characterized by progressive loss of upper and lower motor neurons, leading to muscle weakness, atrophy, and ultimately respiratory failure. While most ALS cases are sporadic, approximately 5-10% have a family history, and among these familial cases, SOD1 mutations represent the second most common genetic cause after C9orf72 repeat expansions. The study of SOD1 mutations has been instrumental in advancing our understanding of ALS pathogenesis, serving as a paradigm for protein aggregation diseases and informing therapeutic development across the entire ALS spectrum[@prudencio2009][@miller2022].

SOD1 Mutations in Amyotrophic Lateral Sclerosis

Overview

Mutations in the SOD1 (Superoxide Dismutase 1) gene are the second most common cause of familial amyotrophic lateral sclerosis (ALS), accounting for approximately 15-20% of inherited ALS cases and representing one of the most extensively studied genetic contributors to motor neuron disease[@banci2007][@strong2010]. Over 180 pathogenic mutations have been identified throughout the SOD1 gene, making it the ALS gene with the largest number of known disease-causing variants. The discovery in 1993 that SOD1 mutations cause ALS through a toxic gain-of-function mechanism revolutionized our understanding of ALS pathogenesis and provided the first clear evidence that protein misfolding and aggregation are central to motor neuron degeneration[@prudencio2009].

Introduction

Amyotrophic lateral sclerosis is a devastating neurodegenerative disorder characterized by progressive loss of upper and lower motor neurons, leading to muscle weakness, atrophy, and ultimately respiratory failure. While most ALS cases are sporadic, approximately 5-10% have a family history, and among these familial cases, SOD1 mutations represent the second most common genetic cause after C9orf72 repeat expansions. The study of SOD1 mutations has been instrumental in advancing our understanding of ALS pathogenesis, serving as a paradigm for protein aggregation diseases and informing therapeutic development across the entire ALS spectrum[@prudencio2009][@miller2022].

The SOD1 protein is a ubiquitous antioxidant enzyme, and understanding how specific mutations transform this essential protective protein into a toxic aggregator has provided critical insights into the molecular mechanisms of neurodegeneration. The identification of SOD1 as an ALS causative gene also established the foundation for genetic testing, genetic counseling, and targeted therapeutic approaches that now extend to other ALS genes.

Genetics

Gene Overview

The SOD1 gene is located on chromosome 21q22.11 and encodes the copper/zinc superoxide dismutase enzyme, a 154-amino acid protein that functions as a homodimer[@banci2007]. Each monomer binds one copper ion and one zinc ion, which are essential for enzymatic activity and structural stability. The protein is widely expressed throughout the body, with particularly high levels in the liver, erythrocytes, and central nervous system.

Normal SOD1 Function:

• Antioxidant defense: Catalyzes the dismutation of superoxide radical (O₂⁻) to hydrogen peroxide (H₂O₂) and molecular oxygen (O₂)
• Cellular protection: Prevents oxidative damage to proteins, lipids, and nucleic acids
• Metal ion homeostasis: Requires precise copper and zinc binding for proper folding and activity
• Dimeric structure: Functions as a homodimer with each subunit requiring proper metalation

Key Pathogenic Mutations

More than 180 pathogenic mutations have been identified throughout the SOD1 gene, with some showing population-specific frequencies[@strong2010]:

| Mutation | Population | Frequency | Phenotype |
|----------|------------|-----------|-----------|
| A4V | North America | ~50% of US cases | Most aggressive, rapid progression |
| G93A | Multiple | Common in research models | Aggressive, early onset |
| H46R | Japan | Majority of Japanese cases | Slower progression |
| D90A | Scandinavia | Majority of Nordic cases | Variable, often slow |
| G85R | Multiple | Rare globally | Moderate progression |
| L126Z | Multiple | Rare | Early onset, aggressive |
| A5G | Portugal | Portuguese cluster | Variable |
| L144F | Various | Rare | Early onset |

Structure-Function Relationships

Mutations affect SOD1 through multiple interconnected mechanisms:

Molecular Mechanisms

Toxic Gain-of-Function

SOD1 mutations cause disease through a toxic gain-of-function mechanism, rather than loss of antioxidant activity[@prudencio2009][@miller2022]. This was conclusively demonstrated by experiments showing that SOD1 knockout mice do not develop ALS, while transgenic mice expressing mutant SOD1 develop progressive motor neuron disease. The toxic mechanisms include:

1. Protein Misfolding and Aggregation

Mutant SOD1 adopts abnormal conformations that nucleate the formation of soluble oligomers and insoluble aggregates[@miller2022]:

• Intermediate species: Partially folded monomers and small oligomers are highly toxic
• Aggregate formation: Insoluble aggregates accumulate in motor neurons and glia
• Sequestration: Aggregates sequester essential cellular proteins including chaperones
• Proteostasis overload: The cellular protein quality control systems become overwhelmed

2. Mitochondrial Dysfunction

Mutant SOD1 interacts directly with mitochondria, causing:

• Direct mitochondrial binding: Mutant SOD1 localizes to mitochondrial outer membranes
• Electron transport chain impairment: Complex I and IV activities are reduced
• Increased ROS production: Paradoxically increases oxidative stress despite antioxidant enzyme activity
• Apoptotic pathway activation: Cytochrome c release and caspase activation
• Mitochondrial trafficking defects: Impaired transport along axons

3. Axonal Transport Defects

Motor neurons are particularly vulnerable to axonal transport deficits:

• Dynein/dynactin dysfunction: Mutant SOD1 impairs retrograde transport
• Neurotrophin trafficking: BDNF and other growth factor delivery is disrupted
• Mitochondrial mobility: Reduced mitochondrial movement leads to energy deficits at synapses
• Synaptic dysfunction: Axonal transport defects cause synaptic degeneration
• Cargo accumulation: Proteins and organelles accumulate proximal to the cell body

4. Glial Cell Dysfunction

Non-cell autonomous toxicity is a key feature of SOD1-ALS:

• Astrocyte dysfunction: Mutant SOD1 astrocytes fail to support motor neurons
• Microglial activation: Chronic neuroinflammation accelerates degeneration
• Oligodendrocyte degeneration: Myelin-producing cells are also affected
• Immune system dysregulation: Peripheral immune cells contribute to pathology

5. Extracellular Vesicle Pathology

Recent research has revealed that mutant SOD1 can be released in extracellular vesicles:

• Exosome release: Mutant SOD1 is packaged into exosomes
• Prion-like spreading: Exosomal SOD1 can seed aggregation in recipient cells
• Microglial uptake: Exosomes may propagate pathology to glial cells
• Biomarker potential: Exosomal SOD1 may serve as a disease biomarker

Aggregation Mechanisms

The aggregation of mutant SOD1 follows a nucleation-dependent process:

Key structural features of SOD1 aggregates include:

• Amyloid fibril formation with cross-beta sheet structure
• Post-translational modifications including oxidation and truncation
• Co-aggregation with other proteins like TDP-43
• Differential aggregation propensities among mutants

Clinical Features

Typical Presentation

Patients with SOD1-ALS present with classic ALS clinical features:

• Age of onset: 40-60 years, though this varies by mutation
• Site of onset: Limb onset (70-80%) or bulbar onset (20-30%)
• Progression rate: Variable, ranging from months to years
• Survival: 2-5 years average, mutation-dependent
• Sex distribution: Slight male predominance

Mutation-Specific Phenotypes

Specific SOD1 mutations are associated with distinct clinical presentations[@strong2010]:

| Mutation | Typical Onset | Progression | Special Features |
|----------|---------------|-------------|-------------------|
| A4V | ~52 years | Very rapid (1-2 years) | Most aggressive form |
| G93A | ~47 years | Rapid | Common research model |
| H46R | ~45 years | Slow (5-10 years) | Japanese cluster, longest survival |
| D90A | ~57 years | Variable | Scandinavian population |
| G85R | ~50 years | Moderate | Variable presentation |
| L126Z | ~35 years | Variable | Early onset possible |
| L144F | ~40 years | Rapid | Early onset |

Atypical Presentations

Some SOD1 mutation carriers develop non-classic ALS phenotypes:

• Primary lateral sclerosis (PLS): Pure upper motor neuron involvement
• Progressive muscular atrophy (PMA): Pure lower motor neuron presentation
• ALS with frontotemporal dementia: Rare with SOD1 compared to C9orf72
• Benign focal amyotrophy: Very rare, slow progression
• Progressive pseudobulbar palsy: Bulbar involvement without limb weakness

Phenotype-Genotype Correlations

• Aggressive mutations (A4V, G93A, L126Z): Rapid progression, early death
• Moderate mutations (G85R, D90A): Variable course
• Slow mutations (H46R, D90A Scandinavian): Extended survival possible

Diagnosis

Genetic Testing

Molecular diagnosis is essential for confirmed SOD1-ALS:

• Method: PCR sequencing of all coding exons, MLPA for deletions
• Indication: Family history of ALS, early-onset cases, atypical presentations
• Counseling: Pre- and post-test genetic counseling is essential
• Interpretation: Must differentiate pathogenic variants from benign polymorphisms

Biomarkers

Fluid Biomarkers:

| Biomarker | Utility | Notes |
|-----------|---------|-------|
| NfL (Neurofilament light chain) | Disease progression | Elevated in CSF and plasma |
| pNfH (Phosphorylated neurofilament heavy) | Prognosis | Higher levels correlate with faster progression |
| Mutant SOD1 in CSF | Disease-specific | Detectable in SOD1 cases only |
| Total SOD1 activity | Disease monitoring | May decrease with progression |
| Tau protein | Cognitive involvement | Elevated in some cases |

Genetic Biomarkers:

• Specific mutation for prognosis
• Homozygous vs heterozygous status
• Repeat expansion in non-SOD1 genes (modifiers)

Neuroimaging

• MRI: May show corticospinal tract hyperintensity, frontotemporal atrophy
• Diffusion tensor imaging: White matter tract damage visible
• MR spectroscopy: Reduced N-acetylaspartate in motor cortex
• PET: Hypometabolism in frontotemporal regions in some cases

Therapeutic Approaches

Clinical Trials and Approved Treatments

| Agent | Target | Phase | Status |
|-------|--------|-------|--------|
| Tofersen (BIIB067) | SOD1 mRNA (ASO) | Phase 3 | Approved in some countries |
| Arl-1656 (CuATSM) | Copper delivery | Phase 2/3 | Completed |
| Edaravone | Oxidative stress | Approved | Modest benefit |
| Riluzole | Glutamate | Approved | Modest survival benefit |
| Reldesemtide | FTH1 | Phase 2 | Ongoing |

Antisense Oligonucleotide (ASO) Therapy

Tofersen (BIIB067) is the most advanced targeted therapy for SOD1-ALS[@zhang2023]:

• Mechanism: Binds SOD1 mRNA, promoting RNase H-mediated degradation
• Delivery: Intrathecal administration to achieve CNS distribution
• Efficacy: Reduces CSF SOD1 protein by up to 80%
• Outcomes: Missed primary endpoint in phase 3, but showed secondary benefits in open-label extension
• Biomarker effects: Reduced CSF NfL in treated patients
• Regulatory status: Approved in some countries under conditional pathways

• Improved delivery to peripheral tissues
• Enhanced potency and duration
• Allele-selective approaches for heterozygous carriers

Gene Therapy Approaches

Multiple gene therapy strategies are in development:

• AAV-delivered ASOs: Improved CNS delivery via viral vectors
• CRISPR/Cas9: Gene editing to correct or disrupt mutant SOD1
• RNAi: siRNA-mediated knock-down of mutant SOD1
• Gene replacement: Delivering wild-type SOD1
• Antisense approaches: Various ASO chemistries and delivery methods

Neuroprotective Strategies

• HSP90 inhibitors to promote proper folding
• Proteasome activators to enhance clearance
• Autophagy modulators to increase aggregate removal
• Chaperone-based therapies

• Antioxidants to reduce oxidative stress
• Mitophagy enhancers to improve mitochondrial quality control
• Metabolic support with energetic substrates
• Mitochondrial transplantation approaches

• Microglial inhibitors
• Cytokine and chemokine blockers
• Immunomodulatory approaches

• Neurotrophic factor delivery
• Axonal regeneration enhancers
• Synaptic protective agents

Animal Models

Transgenic Mouse Models

Multiple SOD1 mouse models have been developed:

• G93A SOD1 mice: Most widely used, rapid disease progression
• G85R SOD1 mice: Slower progression, prominent aggregation
• A4V SOD1 mice: Model of aggressive human phenotype
• H46R SOD1 mice: Slower progression, Japanese variant
• Conditional models: Inducible expression systems
• Cell-type specific models: Motor neuron vs. glial expression

Key Findings from Models

Research in animal models has established:

• Mutant SOD1 alone is sufficient to cause ALS
• Non-neuronal cells contribute significantly to disease progression
• Multiple pathogenic pathways are involved in degeneration
• A therapeutic window exists for intervention
• Reduction of mutant SOD1 delays disease progression
• Glial cells can be both protective and pathogenic

Zebrafish and Drosophila Models

Lower organism models have provided additional insights:

• Zebrafish: Motor neuron morphology, drug screening
• Drosophila: Genetic modifiers, pathway analysis
• C. elegans: Aggregation mechanisms, lifespan studies

Induced Pluripotent Stem Cell Models

Patient-derived iPSCs have revealed:

• Motor neurons show mutant SOD1 aggregation
• Mitochondrial dysfunction is early and prominent
• Axonal transport defects precede degeneration
• Glial cells exhibit inflammatory responses
• Some phenotypes can be rescued with treatment

Management

Disease-Modifying Treatments

• Riluzole: Standard of care, modest survival benefit
• Edaravone: Approved for ALS, modest functional benefit
• Tofersen: For SOD1-ALS, reduces disease progression in some patients

Symptomatic Management

• Multidisciplinary care: Essential for optimal outcomes
• Respiratory support: Non-invasive ventilation, cough assist
• Nutritional support: PEG tube placement when needed
• Speech therapy: Augmentative communication
• Physical therapy: Function maintenance
• Occupational therapy: Activities of daily living
• Psychological support: Depression and anxiety management

Experimental Approaches

• Clinical trial enrollment: Essential for therapeutic progress
• Expanded access programs: For unapproved treatments
• Compassionate use: Case-by-case considerations
• Biomarker studies: For patient stratification

Related Pages

• [Amyotrophic Lateral Sclerosis (ALS) Genetic Variants](/diseases/als-genetic-variants)
• [SOD1 Gene](/entities/sod1)
• [ALS-FTD Spectrum](/diseases/als-ftd-spectrum)
• [Protein Aggregation in Neurodegeneration](/mechanisms/protein-aggregation)
• [Mitochondrial Dysfunction in ALS](/mechanisms/mitochondrial-dysfunction-als)
• [Motor Neuron Disease Overview](/diseases/motor-neuron-disease)
• [Tofersen Clinical Trials](/diseases/tofersen-als-trial)

Recent Research (2024-2026)

Recent studies have advanced our understanding of SOD1-ALS:

• [Efficient induction of motor neuron disease in transgenic G93A SOD1 mice by prion-like seeding.](https://pubmed.ncbi.nlm.nih.gov/41702846/) (2026) - Demonstrates prion-like propagation of mutant SOD1
• [Superoxide dismutase impacts extracellular vesicle shedding and uptake.](https://pubmed.ncbi.nlm.nih.gov/41672113/) (2026) - Reveals exosomal SOD1 release mechanisms
• [An ALS-associated mutant SOD1 protein can be eliminated in microglia culture by selective autophagy.](https://pubmed.ncbi.nlm.nih.gov/41579929/) (2026) - Autophagy-mediated clearance pathways
• [Structural Comparison of the Human G93A Mutant SOD1 to the Wild-type SOD1 Filaments.](https://pubmed.ncbi.nlm.nih.gov/41565003/) (2026) - Structural basis of aggregation
• [Tofersen treatment in SOD1 p.Leu145Phe ALS: real-world outcomes in a genetically homogeneous Croatian cohort.](https://pubmed.ncbi.nlm.nih.gov/41821425/) (2026) - Clinical effectiveness data

External Links

• [ALS Association - SOD1 Information](https://www.als.org)
• [Motor Neurone Disease Association](https://www.mndassociation.org)
• [NIH: SOD1 Amyotrophic Lateral Sclerosis](https://www.ninds.nih.gov/disorders/amyotrophic-lateral-sclerosis-als)
• [PubMed: SOD1 ALS Clinical Trials](https://pubmed.ncbi.nlm.nih.gov/?term=SOD1+ALS+clinical+trial)
• [ALS Therapy Development Institute](https://www.als.net)

References